Global Pharmacogenomics Within Precision Medicine: Challenges and Opportunities

Citations Over TimeTop 10% of 2019 papers

Abstract

K.M.G. is a cofounder of Apricity Therapeutics, Inc. As Deputy Editor-in-Chief of Clinical Pharmacology & Therapeutics (CPT), K.M.G. was not involved in the review or decision process for this paper. M.S. is an unpaid member of numerous scientific advisory boards. A.R.S. receives compensation as a full-time employee of Regeneron Pharmaceuticals. M.V.R. receives investigator-initiated research funding from Servier. R.F.T. has consulted for Apotex, Quinn Emanuel, and Ethismos, is an unpaid member of numerous scientific advisory boards, and was an associate editor for CPT at the time of writing. R.F.T. was not involved in the review or decision process for this paper. The other authors declare no conflicts of interest. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Related Papers

• → Cardiovascular precision medicine – A pharmacogenomic perspective(2023)15 cited
• → Pharmacogenomics Driving Precision Cancer Medicine(2022)2 cited
• → Precision Medicine: Pharmacogenomics and Breast Cancer(2015)
• → Recommendation: Cardiovascular precision medicine – A pharmacogenomic perspective — R0/PR3(2023)
• → Recommendation: Cardiovascular precision medicine – A pharmacogenomic perspective — R1/PR7(2023)